Literature DB >> 25444466

Epidemiology of hepatocellular carcinoma.

Kelly J Lafaro1, Aram N Demirjian2, Timothy M Pawlik3.   

Abstract

Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancer, accounting for between 85% and 90% of these malignancies. The overall prognosis of patients with liver cancer is poor, and an understanding of this disease and its risk factors is crucial for screening at-risk individuals, early recognition, and timely diagnosis. Most HCCs arise in the background of chronic liver disease caused by hepatitis B virus, hepatitis C virus, and chronic excessive alcohol intake. These underlying causes are characterized by marked variations in geography, gender, and other well-documented risk factors, some of which are potentially preventable.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aflatoxin; Chronic liver disease; Cirrhosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Incidence; Risk factors

Mesh:

Year:  2014        PMID: 25444466     DOI: 10.1016/j.soc.2014.09.001

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  119 in total

1.  Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Authors:  Nadim Mahmud; Binu John; Tamar H Taddei; David S Goldberg
Journal:  Clin Transplant       Date:  2019-06-25       Impact factor: 2.863

Review 2.  Systems Challenges of Hepatic Carcinomas: A Review.

Authors:  Dhatri Madduru; Johny Ijaq; Sujata Dhar; Saumyadip Sarkar; Naresh Poondla; Partha S Das; Silvia Vasquez; Prashanth Suravajhala
Journal:  J Clin Exp Hepatol       Date:  2018-05-17

3.  Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Authors:  Nadim Mahmud; Maarouf A Hoteit; David S Goldberg
Journal:  Liver Transpl       Date:  2020-08       Impact factor: 5.799

4.  High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients.

Authors:  Yongqing Xu; Xianmin Bu; Chaoliu Dai; Chao Shang
Journal:  Tumour Biol       Date:  2015-02-01

Review 5.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

6.  Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE.

Authors:  Zhi Li; Tong-Qing Xue; Xiao-Yu Chen
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

7.  Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma.

Authors:  Chao Zhou; Yuejun Sun; Shuwei Guo; Xiao Chen; Genchong Bao; Jiandong Wang
Journal:  Dig Dis Sci       Date:  2017-11-10       Impact factor: 3.199

8.  Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

Authors:  Jing Shen; Chih-Ching Yeh; Qiao Wang; Irina Gurvich; Abby B Siegel; Regina M Santella
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

9.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

10.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.